Cardiovascular side-effects of antipsychotic drugs: The role of the autonomic nervous system

Pharmacology and Therapeutics

Volumn 135, Issue 2, 2012, Pages 113-122

  Leung, Joanne Y T ^a   Barr, Alasdair M ^a,b   Procyshyn, Ric M ^a,b   Honer, William G ^a,b   Pang, Catherine C Y ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b British Columbia Mental Health and Addictions Research Institute   (Canada)

Author keywords

Adverse events; Antipsychotic drug; Autonomic; Cardiovascular; Side effects

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; DROPERIDOL; HALOPERIDOL; ILOPERIDONE; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIORIDAZINE; ZIPRASIDONE;

AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE REGULATION; CARDIOTOXICITY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HEART CONDUCTION; HEART RATE VARIABILITY; HUMAN; MEAN ARTERIAL PRESSURE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; VASOCONSTRICTION;

ANIMALS; ANTIPSYCHOTIC AGENTS; AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR DISEASES; HUMANS; METABOLIC DISEASES;

EID: 84862687967     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2012.04.003     Document Type: Review

References (161)

1. Agelink, M. W., Majewski, T., Wurthmann, C., Lukas, K., Ullrich, H., Linka, T., et al. (2001). Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol 21, 8-13.
2. AHA (2005). Metabolic syndrome: new guidance for prevention and treatment. AHA & NHLBI Scientific Statement.
3. Albaugh, V. L., Singareddy, R., Mauger, D., & Lynch, C. J. (2011). A double blind, placebocontrolled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS One 6, e22662.
4. Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., et al. (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156, 1686-1696.
5. Alvarez, P. A., & Pahissa, J. (2010). QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf 5, 97-104.
6. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 27, 596-601.
7. Amiel, J. M., Mangurian, C. V., Ganguli, R., & Newcomer, J. W. (2008). Addressing cardiometabolic risk during treatment with antipsychotic medications. Curr Opin Psychiatry 21, 613-618.
8. Annila, P., Yli-Hankala, A., & Lindgren, L. (1993). Effect of atropine on the QT interval and T-wave amplitude in healthy volunteers. Br J Anaesth 71, 736-737.
9. Aygit, A. C., Ayhan, M. S., Demiralay, A., & Yildirim, I. (1999). Vascular effects of epinephrine, lisinopril, and chlorpromazine in diabetic and non-diabetic rats. J Reconstr Microsurg 15, 439-441.
10. Azevedo, E. R., & Parker, J. D. (1999). Parasympathetic control of cardiac sympathetic activity: normal ventricular function versus congestive heart failure. Circulation 100, 274-279.
11. Baptista, T., De Mendoza, S., Beaulieu, S., Bermudez, A., & Martinez, M. (2004). The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management. Metab Syndr Relat Disord 2, 290-307.
12. Baptista, T., ElFakih, Y., Uzcategui, E., Sandia, I., Talamo, E., Araujo de Baptista, E., et al. (2008). Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 22, 477-495.
13. Barr, A. M., Panenka, W. J., Honer, W. G., Khara, S., & Procyshyn, R. M. (2011). Excessive antipsychotic dosing in a Canadian outpatient population. Psychiatr Serv 62, 682-683.
14. Barr, A. M., Procyshyn, R. M., Hui, P., Johnson, J. L., & Honer, W. G. (2008). Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment. Schizophr Res 100, 252-260.
15. Behnke, B. J., Armstrong, R. B., & Delp, M. D. (2011). Adrenergic control of vascular resistance varies in muscles composed of different fiber types: influence of the vascular endothelium. Am J Physiol Regul Integr Comp Physiol 301, R783-790.
16. Bhatia, M. S., Gupta, R., & Dhawan, J. (2009). Myocarditis after overdose of conventional antipsychotics. World J Biol Psychiatry 10, 606-608.
17. Bhushan, M., & Asirvatham, S. J. (2009). The conundrum of ventricular arrhythmia and cardiomyopathy: which abnormality came first? Curr Heart Fail Rep 6, 7-13.
18. Bigger, J. T., Jr., Fleiss, J. L., Steinman, R. C., Rolnitzky, L. M., Kleiger, R. E., & Rottman, J. N. (1992). Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 85, 164-171.
19. Boyda, H. N., Procyshyn, R. M., Tse, L., Hawkes, E., Jin, H., Pang, C. C. et al., (in press). Differential effects of three classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. J Psychiatr Neurosci.
20. Boyda, H. N., Procyshyn, R. M., Tse, L., Wong, D., Pang, C. C., Honer, W. G., et al. (2012). Intermittent treatment with olanzapine causes sensitization of the metabolic sideeffects in rats. Neuropharmacology 62, 1391-1400.
21. Boyda, H. N., Tse, L., Procyshyn, R. M., Honer, W. G., & Barr, A. M. (2010). Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci 31, 484-497.
22. Boyda, H. N., Tse, L., Procyshyn, R. M., Wong, D., Wu, T. K., Pang, C. C., et al. (2010). A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 34, 945-954.
23. Brakoulias, V., Bannan, E., Cohen, P., & Geary, G. (2005). Amisulpride and cardiomyopathy. Aust N Z J Psychiatry 39, 738.
24. Bresee, L. C., Majumdar, S. R., Patten, S. B., & Johnson, J. A. (2010). Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res 117, 75-82.
25. Brown, A. S., Gewirtz, G., Harkavy-Friedman, J., Cooper, T., Brebion, G., Amador, X. F., et al. (1997). Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol. Neuropsychopharmacology 17, 317-325.
26. Brown, S., Kim, M., Mitchell, C., & Inskip, H. (2010). Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 196, 116-121.
27. Buckley, N. A., & Sanders, P. (2000). Cardiovascular adverse effects of antipsychotic drugs. Drug Saf 23, 215-228.
28. Bush, A., & Burgess, C. (2008). Fatal cardiomyopathy due to quetiapine. N Z Med J 121, U2909.
29. Bymaster, F. P., Felder, C. C., Tzavara, E., Nomikos, G. G., Calligaro, D. O., & McKinzie, D. L. (2003). Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27, 1125-1143.
30. Castellani, S., Ziegler, M. G., van Kammen, D. P., Alexander, P. E., Siris, S. G., & Lake, C. R. (1982). Plasma norepinephrine and dopamine-beta-hydroxylase activity in schizophrenia. Arch Gen Psychiatry 39, 1145-1149.
31. Charakida, M., & Finer, N. (2012). Drug treatment of obesity in cardiovascular disease. Am J Cardiovasc Drugs 12, 93-104.
32. Chengappa, K. N., Pollock, B. G., Parepally, H., Levine, J., Kirshner, M. A., Brar, J. S., et al. (2000). Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine. J Clin Psychopharmacol 20, 311-316.
33. Chintoh, A. F., Mann, S. W., Lam, L., Giacca, A., Fletcher, P., Nobrega, J., et al. (2009). Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophr Res 108, 127-133.
34. Cincotta, S. L., & Rodefer, J. S. (2010). Emerging role of sertindole in the management of schizophrenia. Neuropsychiatr Dis Treat 6, 429-441.
35. Coffey, S., & Williams, M. (2011). Quetiapine-associated cardiomyopathy. N Z Med J 124, 105-107.
36. Cohen, H., Loewenthal, U., Matar, M., & Kotler, M. (2001). Association of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. Br J Psychiatry 179, 167-171.
37. Coulter, D. M., Bate, A., Meyboom, R. H., Lindquist, M., & Edwards, I. R. (2001). Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 322, 1207-1209.
38. Cuffi, M. L., Vila, E., & Badia, A. (1989). Effects of some antipsychotic drugs on cardiovascular catecholamine receptors in the rat. J Auton Pharmacol 9, 397-409.
39. Cuffi, M. L., Vila, E., & Badia, A. (1989). Increased peripheral alpha 1-adrenoceptor sensitivity following chronic thioridazine treatment in the pithed rat. Eur J Pharmacol 168, 111-113.
40. Dayalu, P., & Chou, K. L. (2008). Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opin Pharmacother 9, 1451-1462.
41. De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012). Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8, 114-126.
42. Dorsey, E. R., Rabbani, A., Gallagher, S. A., Conti, R. M., & Alexander, G. C. (2010). Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med 170, 96-103.
43. Drici, M. D., & Priori, S. (2007). Cardiovascular risks of atypical antipsychotic drug treatment. Pharmacoepidemiol Drug Saf 16, 882-890.
44. Drici, M. D.,Wang,W. X., Liu, X. K., Woosley, R. L., & Flockhart, D. A. (1998). Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol 18, 477-481.
45. Drolet, B., Yang, T., Daleau, P., Roden, D. M., & Turgeon, J. (2003). Risperidone prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. J Cardiovasc Pharmacol 41, 934-937.
46. Elman, I., Goldstein, D. S., Green, A. I., Eisenhofer, G., Folio, C. J., Holmes, C. S., et al. (2002). Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia: a comparison with clozapine and placebo. Neuropsychopharmacology 27, 293-300.
47. Elman, I., Rott, D., Green, A. I., Langleben, D. D., Lukas, S. E., Goldstein, D. S., et al. (2004). Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia. Psychopharmacology (Berl) 176, 369-375.
48. Ennis, C., & Cox, B. (1980). The dopamine receptor antagonist domperidone is also a competitive antagonist at alpha 1-adrenoceptors. J Pharm Pharmacol 32, 434-435.
49. FDA (2000). Psychopharmacological drugs advisory committee: briefing document for Zeldox capsules (ziprasidone HCl). http://www.fda.gov/ohrms/ dockets/ac/00/backgrd/3619b1a.pdf
50. FDA (2009). Psychopharmacological drugs advisory committee: briefing document for NDA 20-644 (sertindole). http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ PsychopharmacologicDrugsAdvisoryCommittee/ UCM161901.pdf
51. FDA (2010). Clozaril (clozapine) label. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2010/019758s062lbl.pdf
52. Fitzsimons, J., Berk, M., Lambert, T., Bourin, M., & Dodd, S. (2005). A review of clozapine safety. Expert Opin Drug Saf 4, 731-744.
53. Foley, D. L., & Morley, K. I. (2011). Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 68, 609-616.
54. Gaertner, H. J., Fischer, E., & Hoss, J. (1989). Side effects of clozapine. Psychopharmacology (Berl) 99, S97-100 (Suppl.).
55. Galanter, J. M., & Lowenstein, D. H. (2008). Principles of nervous system physiology and pharmacology. In D. E. Golan (Ed.), Principles of Pharmacology (pp. 91-106). Philadelphia: LWW.
56. Gaulin, B. D., Markowitz, J. S., Caley, C. F., Nesbitt, L. A., & Dufresne, R. L. (1999). Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 156, 1270-1272.
57. Ghaeli, P., & Dufresne, R. L. (1995). Elevated serum triglycerides on clozapine resolve with risperidone. Pharmacotherapy 15, 382-383.
58. Gokhale, S. D., Gulati, O. D., & Parikh, H. M. (1964). An investigation of the adrenergic blocking action of chlorpromazine. Br J Pharmacol Chemother 23, 508-520.
59. Gothert, M., Lox, H. J., & Rieckesmann, J. M. (1977). Effect of butyrophenones on the sympathetic nerves of the isolated rabbit heart and on the postsynaptic alpha-adrenoceptors of the isolated rabbit aorta. Naunyn Schmiedebergs Arch Pharmacol 300, 255-265.
60. Grootens, K. P., van Veelen, N. M., Peuskens, J., Sabbe, B. G., Thys, E., Buitelaar, J. K., et al. (2011). Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull 37, 352-361.
61. Grundy, S. M., Brewer, H. B., Jr., Cleeman, J. I., Smith, S. C., Jr., & Lenfant, C. (2004). Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/ American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 24, e13-18.
62. Haas, S. J., Hill, R., Krum, H., Liew, D., Tonkin, A., Demos, L., et al. (2007). Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 30, 47-57.
63. Hart, E. C., & Charkoudian, N. (2011). Sympathetic neural mechanisms in human blood pressure regulation. Curr Hypertens Rep 13, 237-243.
64. Hempel, R. J., Tulen, J. H., van Beveren, N. J., Roder, C. H., & Hengeveld, M. W. (2009). Cardiovascular variability during treatment with haloperidol, olanzapine or risperidone in recent-onset schizophrenia. J Psychopharmacol 23, 697-707.
65. Henderson, D. C., Cagliero, E., Copeland, P. M., Borba, C. P., Evins, E., Hayden, D., et al. (2005). Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62, 19-28.
66. Henderson, D. C., Cagliero, E., Gray, C., Nasrallah, R. A., Hayden, D. L., Schoenfeld, D. A., et al. (2000). Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 157, 975-981.
67. Henderson, D. C., Daley, T. B., Kunkel, L., Rodrigues-Scott, M., Koul, P., & Hayden, D. (2004). Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry 65, 686-689.
68. Hill, G. R., & Harrison-Woolrych, M. (2008). Clozapine and myocarditis: a case series from the New Zealand Intensive Medicines Monitoring Programme. N Z Med J 121, 68-75.
69. Hoehns, J. D., Fouts, M. M., Kelly, M. W., & Tu, K. B. (2001). Sudden cardiac death with clozapine and sertraline combination. Ann Pharmacother 35, 862-866.
70. Hoehns, J. D., Stanford, R. H., Geraets, D. R., Skelly, K. S., Lee, H. C., & Gaul, B. L. (2001). Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias. Pharmacotherapy 21, 871-883.
71. Honer, W. G., Procyshyn, R.M., Chen, E. Y., MacEwan, G. W., & Barr, A.M. (2009). A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy. J Psychiatry Neurosci 34, 433-442.
72. Honer, W. G., Thornton, A. E., Sherwood, M., MacEwan, G. W., Ehmann, T. S., Williams, R., et al. (2007). Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia. CNS Drugs 21, 699-714.
73. Ipsen, M., Zhang, Y., Dragsted, N., Han, C., & Mulvany, M. J. (1997). The antipsychotic drug sertindole is a specific inhibitor of alpha1A-adrenoceptors in rat mesenteric small arteries. Eur J Pharmacol 336, 29-35.
74. Kapur, S., Agid, O., Mizrahi, R., & Li, M. (2006). How antipsychotics work-from receptors to reality. NeuroRx 3, 10-21.
75. Karle, C. A., Zitron, E., Zhang, W., Kathofer, S., Schoels, W., & Kiehn, J. (2002). Rapid component I(Kr) of the guinea-pig cardiac delayed rectifier K(+) current is inhibited by beta(1)-adrenoreceptor activation, via cAMP/protein kinase A-dependent pathways. Cardiovasc Res 53, 355-362.
76. Karlsson, J., Wallerstedt, S. M., Star, K., Bate, A., & Hagg, S. (2009). Sudden cardiac death in users of second-generation antipsychotics. J Clin Psychiatry 70, 1725-1726.
77. Katzung, B. G. (2004). Introduction to autonomic pharmacology. In B. G. Katzung (Ed.), Basic & Clinical Pharmacology (pp. 75-93). (9th ed.). New York: McGraw-Hill.
78. Kelly, H. G., Fay, J. E., & Laverty, S. G. (1963). Thioridazine hydrochloride (Mellaril): its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. Can Med Assoc J 89, 546-554.
79. Kilian, J. G., Kerr, K., Lawrence, C., & Celermajer, D. S. (1999). Myocarditis and cardiomyopathy associated with clozapine. Lancet 354, 1841-1845.
80. Kim, D. H., & Stahl, S. M. (2010). Antipsychotic drug development. Curr Top Behav Neurosci 4, 123-139.
81. Kim, J., Ann, J., & Lee, J. (2011). Relationship between heart rate variability and the severity of psychotic symptoms in schizophrenia. Acta Neuropsych 23, 161-166.
82. Kinon, B. J., Basson, B. R., Gilmore, J. A., & Tollefson, G. D. (2001). Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 62, 92-100.
83. Kinoshita, H., Dojo, M., Nakahata, K., Kimoto, Y., Kakutani, T., Mizumoto, K., et al. (2006). Augmented activity of adenosine triphosphate-sensitive K+ channels induced by droperidol in the rat aorta. Anesth Analg 102, 786-791.
84. Kongsamut, S., Kang, J., Chen, X. L., Roehr, J., & Rampe, D. (2002). A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 450, 37-41.
85. Kroeze, W. K., Hufeisen, S. J., Popadak, B. A., Renock, S. M., Steinberg, S., Ernsberger, P., et al. (2003). H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28, 519-526.
86. La Grenade, L., Graham, D., & Trontell, A. (2001). Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med 345, 224-225.
87. Laursen, T. M., Munk-Olsen, T., & Vestergaard, M. (2012). Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 25, 83-88.
88. Layland, J. J., Liew, D., & Prior, D. L. (2009). Clozapine-induced cardiotoxicity: a clinical update. Med J Aust 190, 190-192.
89. Lee, S. Y., Choi, S. Y., Youm, J. B., Ho, W. K., Earm, Y. E., Lee, C. O., et al. (2004). Block of HERG human K(+) channel and IKr of guinea pig cardiomyocytes by chlorpromazine. J Cardiovasc Pharmacol 43, 706-714.
90. Lerma, C., Wessel, N., Schirdewan, A., Kurths, J., & Glass, L. (2008). Ventricular arrhythmias and changes in heart rate preceding ventricular tachycardia in patients with an implantable cardioverter defibrillator. Med Biol Eng Comput 46, 715-727.
91. Lindstrom, E., Farde, L., Eberhard, J., & Haverkamp, W. (2005). QTc interval prolongation and antipsychotic drug treatments: focus on sertindole. Int J Neuropsychopharmacol 8, 615-629.
92. Lund, B. C., Perry, P. J., Brooks, J. M., & Arndt, S. (2001). Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 58, 1172-1176.
93. Mackin, P. (2008). Cardiac side effects of psychiatric drugs. Hum Psychopharmacol 23(Suppl. 1), 3-14.
94. Malaspina, D., Dalack, G., Leitman, D., Corcoran, C., Amador, X. F., Yale, S., et al. (2002). Low heart rate variability is not caused by typical neuroleptics in schizophrenia patients. CNS Spectr 7, 53-57.
95. Manning, J. W., & Cotten, M. D. (1962). Mechanism of cardiac arrhythmias induced by diencephalic stimulation. Am J Physiol 203, 1120-1124.
96. Marti, D., Miquel, R., Ziani, K., Gisbert, R., Ivorra, M. D., Anselmi, E., et al. (2005). Correlation between mRNA levels and functional role of alpha1-adrenoceptor subtypes in arteries: evidence of alpha1L as a functional isoform of the alpha1A-adrenoceptor. Am J Physiol Heart Circ Physiol 289, H1923-1932.
97. Matkó, I., Fehér, E., & Vizi, E. S. (1994). Receptormediated presynapticmodulation of the release of noradrenaline in human papillary muscle. Cardiovasc Res 28, 700-704.
98. McEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., et al. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 80, 19-32.
99. Mehta, A. (2010). Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome. Postgrad Med 122, 61-70.
100. Meltzer, H. Y., Bonaccorso, S., Bobo, W. V., Chen, Y., & Jayathilake, K. (2011). A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation. J Clin Psychiatry 72, 1602-1610.
101. Meltzer, H. Y., & Massey, B. W. (2011). The role of serotonin receptors in the action of atypical antipsychotic drugs. Curr Opin Pharmacol 11, 59-67.
102. Miceli, J. J., Tensfeldt, T. G., Shiovitz, T., Anziano, R. J., O'Gorman, C., & Harrigan, R. H. (2010). Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder. Clin Ther 32, 472-491.
103. Morgan, J. P., & Van Maanen, E. F. (1980). the role of differential blockade of alpha-adrenergic agonists in chlorpromazine-induced hypotension. Arch Int Pharmacodyn Ther 247, 135-144.
104. Mueck-Weymann, M., Rechlin, T., Ehrengut, F., Rauh, R., Acker, J., Dittmann, R. W., et al. (2002). Effects of olanzapine and clozapine upon pulse rate variability. Depress Anxiety 16, 93-99.
105. Nedergaard, O. A., & Abrahamsen, J. (1988). Effect of chlorpromazine on sympathetic neuroeffector transmission in the rabbit isolated pulmonary artery and aorta. Br J Pharmacol 93, 23-34.
106. Newcomer, J. W., Haupt, D. W., Fucetola, R., Melson, A. K., Schweiger, J. A., Cooper, B. P., et al. (2002). Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 59, 337-345.
107. Nielsen, J., Graff, C., Kanters, J. K., Toft, E., Taylor, D., & Meyer, J. M. (2011). Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs 25, 473-490.
108. Nourian, Z., Mow, T., Muftic, D., Burek, S., Pedersen, M. L., Matz, J., et al. (2008). Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha(1)-adrenoceptor function. Psychopharmacology (Berl) 199, 15-27.
109. Nourian, Z., Mulvany, M. J., Nielsen, K. B., Pickering, D. S., & Kristensen, T. (2008). The antagonistic effect of antipsychotic drugs on a HEK293 cell line stably expressing human alpha1A1-adrenoceptors. Eur J Pharmacol 596, 32-40.
110. Nuttall, G. A., Eckerman, K. M., Jacob, K. A., Pawlaski, E. M., Wigersma, S. K., Marienau, M. E., et al. (2007). Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population? Anesthesiology 107, 531-536.
111. O'Brien, P., & Oyebode, F. (2003). Psychotropic medication and the heart. Adv Psychiatr Treat 9, 414-423.
112. Osborn, D. P., Levy, G., Nazareth, I., Petersen, I., Islam, A., & King, M. B. (2007). Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's general practice research database. Arch Gen Psychiatry 64, 242-249.
113. Pang, C. C. (2001). Autonomic control of the venous system in health and disease: effects of drugs. Pharmacol Ther 90, 179-230.
114. Perrington, A., Einstein, R., Jackson, D. M., & Christie, M. J. (1983). Chronic haloperidol and adrenergic receptor sensitivity in the rat. J Neural Transm 57, 13-25.
115. Petersen, E. N. (1981). Pre- and postsynaptic alpha-adrenoceptor antagonism by neuroleptics in vivo. Eur J Pharmacol 69, 399-405.
116. Peuskens, J. (1995). Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 166, 712-726 (discussion 727-733).
117. Pretorius, J. L., Phillips, M., Langley, R. W., Szabadi, E., & Bradshaw, C. M. (2001). Comparison of clozapine and haloperidol on some autonomic and psychomotor functions, and on serum prolactin concentration, in healthy subjects. Br J Clin Pharmacol 52, 322-326.
118. Procyshyn, R. M., Honer, W. G., Wu, T. K., Ko, R. W., McIsaac, S. A., Young, A. H., et al. (2010). Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 71, 566-573.
119. Procyshyn, R. M., Wasan, K. M., Thornton, A. E., Barr, A. M., Chen, E. Y., Pomarol-Clotet, E., et al. (2007). Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-termclozapine treatment. J Psychiatry Neurosci 32, 331-338.
120. Raedler, T. J. (2010). Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry 23, 574-581.
121. Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009). Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360, 225-235.
122. Reed, M. J., Robertson, C. E., & Addison, P. S. (2005). Heart rate variability measurements and the prediction of ventricular arrhythmias. QJM 98, 87-95.
123. Reilly, J. G., Ayis, S. A., Ferrier, I. N., Jones, S. J., & Thomas, S. H. (2000). QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 355, 1048-1052.
124. Reilly, J. G., Ayis, S. A., Ferrier, I. N., Jones, S. J., & Thomas, S. H. (2002). Thioridazine and sudden unexplained death in psychiatric in-patients. Br J Psychiatry 180, 515-522.
125. Reinders, J., Parsonage, W., Lange, D., Potter, J. M., & Plever, S. (2004). Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust N Z J Psychiatry 38, 915-922.
126. Remington, G., Foussias, G., & Agid, O. (2010). Progress in defining optimal treatment outcome in schizophrenia. CNS Drugs 24, 9-20.
127. Reynolds, G. P., & Kirk, S. L. (2010). Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther 125, 169-179.
128. Roesch-Ely, D., Van Einsiedel, R., Kathofer, S., Schwaninger, M., & Weisbrod, M. (2002). Myocarditis with quetiapine. Am J Psychiatry 159, 1607-1608.
129. Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., et al. (2010). Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and metaanalysis. Schizophr Res 123(2-3), 225-233.
130. Sacher, J., Mossaheb, N., Spindelegger, C., Klein, N., Geiss-Granadia, T., Sauermann, R., et al. (2008). Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology 33, 1633-1641.
131. Schulz, E., Fleischhaker, C., Clement, H. W., & Remschmidt, H. (1997). Blood biogenic amines during clozapine treatment of early-onset schizophrenia. J Neural Transm 104, 1077-1089.
132. See, R. E., Fido, A. A., Maurice, M., Ibrahim, M. M., & Salama, G. M. (1999). Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia. Biol Psychiatry 45, 1653-1656.
133. Silke, B., Campbell, C., & King, D. J. (2002). The potential cardiotoxicity of antipsychotic drugs as assessed by heart rate variability. J Psychopharmacol 16, 355-360.
134. Silver, H., Kogan, H., & Zlotogorski, D. (1990). Postural hypotension in chronically medicated schizophrenics. J Clin Psychiatry 51, 459-462.
135. Singh, B. N. (2005). Beta-adrenergic blockers as antiarrhythmic and antifibrillatory compounds: an overview. J Cardiovasc Pharmacol Ther 10(Suppl. 1), S3-S14.
136. Skrede, S., Ferno, J., Vazquez,M. J., Fjaer, S., Pavlin, T., Lunder, N., et al. (2012). Olanzapine, but not aripiprazole,weight-independently elevates serumtriglycerides and activates lipogenic gene expression in female rats. Int J Neuropsychopharmacol 15, 163-179.
137. Smith, G. C., Vickers, M. H., Cognard, E., & Shepherd, P. R. (2009). Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour. Schizophr Res 115, 30-40.
138. Smith, G. C., Vickers, M. H., & Shepherd, P. R. (2011). Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat. Arch Physiol Biochem 117(4), 241-249.
139. Smith, G. N., Wong, H., MacEwan, G. W., Kopala, L. C., Ehmann, T. S., Thornton, A. E., et al. (2009). Predictors of starting to smoke cigarettes in patients with first episode psychosis. Schizophr Res 108, 258-264.
140. Spivak, B., Lamschtein, C., Talmon, Y., Guy, N., Mester, R., Feinberg, I., et al. (1999). The impact of clozapine treatment on serum lipids in chronic schizophrenic patients. Clin Neuropharmacol 22, 98-101.
141. Stampfer, H., & Swanepoel, P. (2005). Severe tachycardia following low-dose clozapine treatment. Australas Psychiatry 13, 80-82.
142. Stein, P. K., Barzilay, J. I., Chaves, P. H., Mistretta, S. Q., Domitrovich, P. P., Gottdiener, J. S., et al. (2008). Novel measures of heart rate variability predict cardiovascular mortality in older adults independent of traditional cardiovascular risk factors: the Cardiovascular Health Study (CHS). J Cardiovasc Electrophysiol 19, 1169-1174.
143. Stroup, T. S., Marder, S. R., & Lieberman, J. A. (2012). Pharmacotherapies. In J. A. Lieberman, T. S. Stroup, & D. O. Perkins (Eds.), Essentials of Schizophrenia (pp. 173-206). (1st ed.). Arlington: American Psychiatric Publishing Inc.
144. Stroup, T. S., McEvoy, J. P., Ring, K. D., Hamer, R. H., LaVange, L. M., Swartz, M. S., et al. (2011). A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 168, 947-956.
145. Sugiyama, A., Satoh, Y., & Hashimoto, K. (2001). In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol. Toxicol Appl Pharmacol 173, 120-128.
146. Tandon, R. (2002). Safety and tolerability: how do newer generation "atypical" antipsychotics compare? Psychiatr Q 73, 297-311.
147. Taylor, D. M., & McAskill, R. (2000). Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 101, 416-432.
148. Testai, L., Cecchetti, V., Sabatini, S., Martelli, A., Breschi, M. C., & Calderone, V. (2010). Effects of K openers on the QT prolongation induced by HERG-blocking drugs in guinea-pigs. J Pharm Pharmacol 62, 924-930.
149. Thomas, S. H., Drici, M. D., Hall, G. C., Crocq, M. A., Everitt, B., Lader, M. H., et al. (2010). Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand 122, 345-355.
150. Tisdale, J. E., Kovacs, R., Mi, D., McCabe, G. P., Cariera, B. L., Sharma, N., et al. (2007). Accuracy of uncorrected versus corrected QT interval for prediction of torsade de pointes associated with intravenous haloperidol. Pharmacotherapy 27, 175-182.
151. Tsuji, H., Larson, M. G., Venditti, F. J., Jr., Manders, E. S., Evans, J. C., Feldman, C. L., et al. (1996). Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation 94, 2850-2855.
152. Tutor, A. S., Delpon, E., Caballero, R., Gomez, R., Nunez, L., Vaquero, M., et al. (2006). Association of 14-3-3 proteins to beta1-adrenergic receptors modulates Kv11.1 K+ channel activity in recombinant systems. Mol Biol Cell 17, 4666-4674.
153. van den Buuse, M. (2003). Acute effects of antipsychotic drugs on cardiovascular responses to stress. Eur J Pharmacol 464, 55-62.
154. Verrier, R. L., Calvert, A., & Lown, B. (1975). Effect of posterior hypothalamic stimulation on ventricular fibrillation threshold. Am J Physiol 228, 923-927.
155. Victoriano, M., de Beaurepaire, R., Naour, N., Guerre-Millo, M., Quignard-Boulange, A., Huneau, J. F., et al. (2010). Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state. Brain Res 1350, 167-175.
156. Vieweg, W. V., Wood, M. A., Fernandez, A., Beatty-Brooks, M., Hasnain, M., & Pandurangi, A. K. (2009). Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 26, 997-1012.
157. Wang, J. F., Min, J. Y., Hampton, T. G., Amende, I., Yan, X., Malek, S., et al. (2008). Clozapine-induced myocarditis: role of catecholamines in a murine model. Eur J Pharmacol 592, 123-127.
158. Warner, J. P., Barnes, T. R., & Henry, J. A. (1996). Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand 93, 311-313.
159. Wong, C. W., & Wang, C. H. (1999). Left stellate stimulation increases left ventricular ejection fraction in patients with essential palmar hyperhidrosis. J Auton Nerv Syst 78, 64-67.
160. Woo, Y. S., Kim, W., Chae, J. H., Yoon, B. H., & Bahk, W. M. (2009). Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients. World J Biol Psychiatry 10, 420-425.
161. Zemrak, W. R., & Kenna, G. A. (2008). Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health Syst Pharm 65, 1029-1038.